NCT00473460 - Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis | Biotech Hunter

Enrollment

1,404

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

Lung DiseasesBronchitis, Chronic

Interventions

DRUG

Avelox (Moxifloxacin, BAY12-8039)

Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks

DRUG

Placebo

Matching placebo capsules orally once daily for 5 days every 8 weeks.

Trial Locations (78)

8

Dublin

1416

Buenos Aires

1426

Buenos Aires

1888

San Juan Bautista

2057

Johannesburg

4091

Durban

7531

Cape Town

7569

Cape Town

7646

Paarl

9300

Bloemfontein

9301

Bloemfontein

10717

Berlin

10969

Berlin

11527

Athens

12043

Berlin

18101

Afula

19300

Rosiers-d'Égletons

20123

Milan

20157

Milan

20535

Hamburg

23795

Bad Segeberg

27100

Pavia

27356

Rotenburg (Wümme)

28040

Madrid

29400

Ronda

30159

Hanover

31350

Chihuahua City

33744

Bay Pines

40000

Mont-de-Marsan

44100

Ferrara

44280

Guadalajara

46009

Valencia

47010

Valladolid

56564

Neuwied

58452

Witten

59512

Bat Yam

62000

Arras

63571

Gelnhausen

64239

Tel Aviv

64300

Orthez

67000

Strasbourg

77024

Houston

77030

Houston

78306

Ashkelon

85723

Tucson

87600

Kaufbeuren

97001

Mérida

97070

Mérida

90822-5201

Long Beach

90073-1003

Los Angeles

64128-2295

Kansas City

14215-1129

Buffalo

75216-7167

Dallas

78284-5799

San Antonio

23249-0002

Richmond

Unknown

Les Escaldes

Santiago

C1120AAF

Buenos Aires

36036-110

Juiz de Fora

90610-000

Porto Alegre

04023-900

São Paulo

05403-900

São Paulo

236-3058

Valparaíso

06000

Nice

265 04

Rio

DUBLIN 7

Dublin

0040

Pretoria

0157

Pretoria

08916

Badalona

08036

Barcelona

BS10 5NB

Bristol

E1 2AT

London

E2 9JX

London

NW3 2QG

London

SW17 0QT

London

SW3 6NP

London

B15 2TH

Birmingham

LS9 7TF

Leeds